Analysts Downgrades Report: Dimension Therapeutics Inc (NASDAQ:DMTX)

Dimension Therapeutics Inc (NASDAQ:DMTX) currently trades at $1.95 which is about -54.12% lower than the 52-week high of $10.47. The trading volume at ready counter moved to 1.67M shares as compared to 100,330.00 shares average traded volume. The stock failed to get pushed above the $2.81 barrier, the intraday high, after opening at $2.75. Analysts have a consensus target price of $60.07 in the 12-month period. Its market capitalization has now reached to $47.17M.

Dimension Therapeutics Inc (NASDAQ:DMTX) was dropped to Underweight from Equal Weight at Barclays. It has earned a consensus Strong buy rating, according to Zacks Investment Research. No analyst has rated the stock with a sell rating, 1 has assigned a hold rating, Zero says it’s a buy and 3 have assigned a strong buy rating to the company.

Dimension Therapeutics, Inc., a gene therapy platform company, focuses on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression in patients with hemophilia B; DTX201, a gene therapy program for the treatment of hemophilia A; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; and DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase. Dimension Therapeutics, Inc. was founded in 2013 and is based Cambridge, Massachusetts.